The purpose of this program project grant is to investigate the biology of marrow transplantation and improved allogeneic, syngeneic, and autologous transplantation in clinical malignancy, diseases of marrow failure and certain genetic diseases. The proposal is made up of six projects: 1) Clinical Trials: This project is designed to investigate ways to improve the result of marrow purging and improve methods of patients supportive care. 2) Graft-versus-Host Reaction and Disease:
The aims of this project are to investigate the basic mechanisms involved and the therapeutic prevention and treatment of Graft-versus-Host Disease. 3) Pharmacology in Bone Marrow Transplantation:
The aims of this project are to provide knowledge as to the pharmacokinetics and mechanism of agents employed in pre-operative regimens, resistance to these agents and development of new anti tumor agents and agents used to prevent and treat graft-versus-host disease. 4) Biology of Viral Infection in Bone Marrow Transplantation:
The aims of this project are to define the role BK virus as a pathogen in transplant patients, the role of EBV virus in the pathogenesis of Hodgkin's Disease and the effect of adoptive transfer of anti-EBV cellular immunity in EBV positive Hodgkin's Disease. 5) Experimental Hematology in Bone Marrow Transplantation:
The aims are to study the function of BCR-ACL in CML as to cell proliferation, survival and differentiation, develop new clinical strategies for treatment of CML based on preclinical studies and apply principles learned from CML to the study of both normal and malignant hematopoiesis. 6) Core components: This project represents the core of the program and includes administrative and support services, RLFP analysis, statistics, graft engineering, pathology, and outpatient services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-22
Application #
2086341
Study Section
Special Emphasis Panel (SRC (B1))
Project Start
1976-09-30
Project End
1996-11-30
Budget Start
1994-12-16
Budget End
1995-11-30
Support Year
22
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909
Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617
Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25
Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; BolaƱos-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393

Showing the most recent 10 out of 456 publications